{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:11:19Z","timestamp":1776949879987,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cld.2024.01.006","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T20:49:15Z","timestamp":1706820555000},"page":"287-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacologic Management of Hepatic Encephalopathy"],"prefix":"10.1016","volume":"28","author":[{"given":"Ali","family":"Khalessi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos T.","family":"Pyrsopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cld.2024.01.006_bib1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1172\/JCI104761","article-title":"Relation of acute potassium depletion to renal ammonium metabolism in patients with cirrhosis","volume":"42","author":"Baertl","year":"1963","journal-title":"The Journal of clinical investigation"},{"issue":"5","key":"10.1016\/j.cld.2024.01.006_bib2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/jgh.13243","article-title":"Prevalence and prognostic significance of hyperkalemia in hospitalized patients with cirrhosis","volume":"31","author":"Maiwall","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2024.01.006_bib3","first-page":"10","article-title":"Hypokalemia as a responsible factor related with the severity of hepatic encephalopathy: a wide multi-nation cross-sectional study","author":"Ullah","year":"2023","journal-title":"Annals of Medicine and Surgery"},{"issue":"12","key":"10.1016\/j.cld.2024.01.006_bib4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/gut.11.12.1043","article-title":"Lactulose","volume":"11","author":"Elkington","year":"1970","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.cld.2024.01.006_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM196908212810803","article-title":"Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial","volume":"281","author":"Elkington","year":"1969","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2024.01.006_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003044.pub3","article-title":"Non-absorbable disaccharides versus placebo\/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis","author":"Gluud","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.cld.2024.01.006_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.cgh.2019.08.047","article-title":"Comparative efficacy of treatment options for minimal hepatic encephalopathy: a systematic review and network meta-analysis","volume":"18","author":"Dhiman","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2024.01.006_bib8","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ajg.2013.219","article-title":"A\u00a0randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","volume":"108","author":"Sharma","year":"2013","journal-title":"Official journal of the American College of Gastroenterology| ACG"},{"issue":"8","key":"10.1016\/j.cld.2024.01.006_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2007.03464.x","article-title":"The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy\u2013a decision analysis","volume":"26","author":"Huang","year":"2007","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"7","key":"10.1016\/j.cld.2024.01.006_bib10","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ajg.2012.113","article-title":"Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy","volume":"107","author":"Agrawal","year":"2012","journal-title":"Official journal of the American College of Gastroenterology| ACG"},{"issue":"11","key":"10.1016\/j.cld.2024.01.006_bib11","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1001\/jamainternmed.2014.4746","article-title":"Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial","volume":"174","author":"Rahimi","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.cld.2024.01.006_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000648","article-title":"Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis","volume":"8","author":"Hoilat","year":"2021","journal-title":"BMJ Open Gastroenterology"},{"key":"10.1016\/j.cld.2024.01.006_bib13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/BF01308097","article-title":"Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study","volume":"26","author":"Orlandi","year":"1981","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.cld.2024.01.006_bib14","first-page":"542","article-title":"Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy","volume":"39","author":"Strauss","year":"1992","journal-title":"Hepato-Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2024.01.006_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-73-3-393","article-title":"Deafness complicating antibiotic therapy of hepatic encephalopathy","volume":"73","author":"Berk","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2024.01.006_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/apt.13435","article-title":"Potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis","volume":"43","author":"Bajaj","year":"2016","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"1","key":"10.1016\/j.cld.2024.01.006_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","article-title":"Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial","volume":"38","author":"Mas","year":"2003","journal-title":"Journal of hepatology"},{"issue":"2","key":"10.1016\/j.cld.2024.01.006_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.12803","article-title":"Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy","volume":"40","author":"Kimer","year":"2014","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"12","key":"10.1016\/j.cld.2024.01.006_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2024.01.006_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cgh.2022.05.042","article-title":"Dosing of rifaximin soluble solid dispersion tablets in adults with cirrhosis: 2 randomized, placebo-controlled trials","volume":"21","author":"Bajaj","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2024.01.006_bib21","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jhep.2013.07.020","article-title":"Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study","volume":"59","author":"Sim\u00f3n-Talero","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2024.01.006_bib22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.dld.2021.04.030","article-title":"Efficacy and safety of albumin infusion for overt hepatic encephalopathy: a systematic review and meta-analysis","volume":"53","author":"Teh","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2024.01.006_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2022.09.009","article-title":"A\u00a0double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study","volume":"78","author":"Fagan","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2024.01.006_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/nu13020370","article-title":"A\u00a0comprehensive review evaluating the impact of protein source (vegetarian vs. meat based) in hepatic encephalopathy","volume":"13","author":"Iqbal","year":"2021","journal-title":"Nutrients"},{"issue":"9","key":"10.1016\/j.cld.2024.01.006_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001939.pub3","article-title":"Branched-chain amino acids for people with hepatic encephalopathy","author":"Gluud","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.cld.2024.01.006_bib26","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1572-0241.2008.01861.x","article-title":"Probiotic yogurt for the treatment of minimal hepatic encephalopathy","volume":"103","author":"Bajaj","year":"2008","journal-title":"Official journal of the American College of Gastroenterology| ACG"},{"issue":"2","key":"10.1016\/j.cld.2024.01.006_bib27","article-title":"Probiotics for people with hepatic encephalopathy","author":"Dalal","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.cld.2024.01.006_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cgh.2013.11.006","article-title":"Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial","volume":"12","author":"Lunia","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2024.01.006_bib29","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2024.01.006_bib30","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0016-5085(91)90290-2","article-title":"Overt hepatic encephalopathy precipitated by zinc deficiency","volume":"100","author":"Van Der Rijt","year":"1991","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2024.01.006_bib31","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1365-2036.2010.04448.x","article-title":"Clinical trial: oral zinc in hepatic encephalopathy","volume":"32","author":"Takuma","year":"2010","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"1","key":"10.1016\/j.cld.2024.01.006_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2891-12-74","article-title":"A\u00a0systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy","volume":"12","author":"Chavez-Tapia","year":"2013","journal-title":"Nutr J"},{"issue":"7","key":"10.1016\/j.cld.2024.01.006_bib33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/apt.13122","article-title":"Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy","volume":"41","author":"Zhu","year":"2015","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2024.01.006_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-018-1024-1","article-title":"L-Ornithine L-Aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses","volume":"79","author":"Butterworth","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.cld.2024.01.006_bib35","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1016\/j.cgh.2020.10.019","article-title":"Efficacy and safety of ornithine phenylacetate for treating overt hepatic encephalopathy in a randomized trial","volume":"19","author":"Rahimi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124000060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124000060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T05:41:16Z","timestamp":1711518076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326124000060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1089326124000060"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2024.01.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Management of Hepatic Encephalopathy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2024.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}